Astrana Health, Inc. (ASTH)

NASDAQ: ASTH · USD

$36.6

-0.33 (-0.9%)· Recorded snapshot

Market cap	1.9B
Revenue (ttm)	3.8B
Net income (ttm)	40.5M
EPS (ttm)	$0.82
Shares out	51.2M
P/E (trailing)	44.6x
P/E (forward)	21.8x
Volume	182,042
Beta	1.03

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 3.8B
Net income (ttm): 40.5M
EPS (ttm): $0.82
P/E (trailing): 44.6x
P/E (forward): 21.8x
Market cap: 1.9B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	보유

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E21.8

P25 n/aP50 n/aP75 n/a

Trailing P/E44.6

P25 n/aP50 n/aP75 n/a

ROE6.9

P25 n/aP50 n/aP75 n/a

ROIC6.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ASTH indicators

Market & fundamental data

Available fields

263

Groups with data

Currency

USD

Showing 263 of 263 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001083446
Company name	Astrana Health, Inc.
Country	United States
Country code	US
CUSIP number	03763A207
Earnings date	2026-11-05
Earnings time	amc
Employees	3,000
Employees change	1,100
Employees growth	57.89%
Enterprise value	$2.5B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1994
In index	RUSSELL2000
Industry	Medical Care Facilities
Is primary listing	Yes
Is SPAC	No
ISIN number	US03763A2078
Last 10-K release date	2026-03-12
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$1.9B
Market cap category	Small-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$36.61
Price currency	USD
Sector	Healthcare
SIC code	8742
Stock price date	2026-10-28
Symbol	ASTH
U.S. state	California
Website	https://www.astranahealth.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	13.87x
Average P/E ratio (10Y)	44.26x
Average P/E ratio (3Y)	49.04x
Average P/E ratio (5Y)	44.1x
Earnings yield	2.24%
EV/Earnings	61.23x
EV/EBIT	22.19x
EV/EBITDA	14.2x
EV/FCF	26.31x
EV/Sales	0.65x
FCF / EV yield	3.8%
FCF yield	4.96%
Forward EV/Sales	0.59x
Forward P/E	21.75x
Forward P/S	0.46x
Graham number	17.63918
Graham upside	-52.6%
Industry forward P/E	15.38x
Industry P/E	18.76x
Lynch fair value	$4.10
Lynch upside	-88.98%
P/(FCF - SBC) ratio	35.52x
P/(OCF - SBC) ratio	28.37x
P/B ratio	2.19x
P/E ratio	44.65x
P/FCF ratio	20.18x
P/OCF ratio	17.65x
P/S ratio	0.5x
Price/EBITDA ratio	10.89x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	2.91%
EBITDA margin	4.55%
Effective tax rate	34.73%
FCF margin	2.46%
Gross margin	10.46%
Operating margin	2.91%
Pretax margin	1.56%
Profit margin	1.05%
Profit per employee	$13,516
Profitable quarters	6
Profitable years	10
Revenue per employee	$1.3M
ROA	3.76%
ROA (5Y)	5.65%
ROCE	7.29%
ROE	6.9%
ROE (5Y)	9.08%
ROIC	6.24%
ROIC (5Y)	10.62%
SBC / revenue	1.06%
Tax / revenue	0.54%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	56.78%
EPS growth (Q)	110.53%
EPS growth (QoQ)	37.93%
EPS growth 3Y	-6.12%
EPS growth 5Y	-8.48%
EPS growth quarters	3
EPS growth years	0
FCF growth	-22.16%
FCF growth (Q)	-67.74%
FCF growth (QoQ)	-54.93%
FCF growth 3Y	15.58%
FCF growth 5Y	10.69%
Gross profit growth	47.11%
Gross profit growth (Q)	33.41%
Gross profit growth 3Y	22.16%
Gross profit growth 5Y	18.39%
Net income growth	60.53%
Net income growth (Q)	109.48%
Net income growth (QoQ)	36.73%
Net income growth 3Y	-3.95%
Net income growth 5Y	-5.06%
Net income growth quarters	3
Net income growth years	0
OCF growth	-17.38%
OCF growth (Q)	-63.97%
OCF growth (QoQ)	-51.88%
OCF growth 10Y	20.89%
OCF growth 3Y	9.31%
OCF growth 5Y	10.71%
Operating income growth	52.39%
Operating income growth (Q)	68.74%
Operating income growth 3Y	-0.06%
Operating income growth 5Y	1.09%
Revenue growth	58.91%
Revenue growth (Q)	48.52%
Revenue growth (QoQ)	0.77%
Revenue growth 10Y	39.85%
Revenue growth 3Y	43.66%
Revenue growth 5Y	40.24%
Revenue growth quarters	22
Revenue growth years	12

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-13.5M
Depreciation and amortization	$63M
EBIT	$111.9M
EBITDA	$174.9M
EPS	$0.82
FCF per share	$1.84
Financing cash flow	$502.1M
Free cash flow	$94.4M
Free cash flow minus SBC	$53.6M
Gross profit	$402M
Income taxes	$20.9M
Investing cash flow	$-544.6M
Net borrowing	$539.4M
Net cash flow	$65.4M
Net income	$40.5M
Operating cash flow minus SBC	$67.1M
Operating income	$111.9M
Revenue	$3.8B
Stock-based compensation	$40.8M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.63
Book value per share	$16.87
Debt / EBITDA	5.09
Debt / equity	1.64
Debt / FCF	10.38
Goodwill	$887M
Interest coverage	1.55
Long-term assets	$1.4B
Long-term liabilities	$935.9M
Net cash (debt)	$-578.6M
Net cash / market cap	-30.39%
Net debt / EBITDA	3.31
Net debt / equity	0.97
Net debt / FCF	6.13
Piotroski F-Score	5
Property, plant and equipment	$101.8M
Shareholders' equity	$598.6M
Tangible book value	$-300.1M
Tangible book value per share	$-6.10
Total assets	$2.3B
Total cash	$400.8M
Total debt	$979.4M
Total liabilities	$1.7B
WACC	8.2%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	2.06
Current assets	$919.2M
Current liabilities	$747.6M
Current ratio	1.23
Net working capital	$-166.5M
Quick ratio	1.19
Working capital	$171.5M
Working capital turnover	17.44

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-1.73%
Dividend yield	0%
Shareholder yield	-1.73%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$37.30
1D price change	-0.89%
1W price change	-5.73%
1W total return	-5.73%
1Y price change	10.05%
1Y return CAGR	10.05%
1Y total return	10.05%
20-day SMA	$37.14
200-day SMA	$33.74
3M price change	-4.77%
3M total return	-4.77%
3Y price change	21.4%
3Y return CAGR	6.67%
3Y total return	21.4%
50-day SMA	$37.18
50-day SMA vs 200-day SMA	50over200
52-week high	$51.60
52-week high date	2026-07-02
52-week low	$18.08
52-week low date	2026-02-12
5Y price change	-47.34%
5Y return CAGR	-12.04%
5Y total return	-47.34%
6M price change	6.94%
6M total return	6.94%
All-time high	$133.23
All-time high date	2021-11-15
All-time low	$9.27
All-time low date	2020-03-18
Average true range (ATR)	$1.58
Average volume	293.2K
Beta (1Y)	1.32
Beta (2Y)	1.08
Beta (5Y)	1.03
Change from 52-week high	-29.05%
Change from 52-week low	102.49%
Change from all-time high	-72.7%
Change from all-time low	292.34%
Change from open	-0.95%
Day's gap	0.05%
Dollar volume	$6.7M
High price	$37.33
Low price	$36.45
Monthly RSI	52.03
Open price	$36.96
Position in 52-week range	18.18%
Premarket change	0.41%
Premarket close	$36.94
Premarket price	$37.09
Premarket volume	3.2K
Previous close	$36.94
Price vs 150-day SMA	-2.49%
Price vs 20-day SMA	-2.08%
Price vs 200-day SMA	7.81%
Price vs 50-day SMA	-2.18%
Relative volume	0.62
RSI	46.06
Sharpe ratio	0.42
Sharpe ratio (3Y)	0.32
Sharpe ratio (5Y)	0.03
Sortino ratio	0.68
Sortino ratio (3Y)	0.56
Sortino ratio (5Y)	0.13
Volume	182K
Weekly RSI	50.67
YTD price change	46.59%
YTD total return	46.59%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	45.7M
Float percentage	89.25%
Shares change (QoQ)	1.48%
Shares change (YoY)	1.73%
Shares held by insiders	10.72%
Shares held by institutions	63.55%
Shares outstanding	51.2M
Short % of float	6.76%
Short % of shares	6.03%
Short ratio	7.6 days

Deeper analysis on ASTH

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ASTH report

Is a complete ASTH research report available?

No complete published report is available for Astrana Health, Inc. (ASTH) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Astrana Health, Inc. (ASTH)

Price

Financial snapshot

Fair-value bridge

Latest news · ASTH

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ASTH indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ASTH

Frequently asked questions